Who Qualifies for GLP-1 Weight-Loss Treatment?

“Am I a candidate?” is usually the first question people ask about GLP-1 weight-loss medicines, and the answer online is often muddled. Some sites make it sound as if anyone who wants to lose a few pounds can get a prescription. Others suggest you need diabetes. Neither is true.

The real starting point is the FDA-approved prescribing information, the label, for each medicine. It spells out who the drug is approved for, who should not take it and which situations need extra care. This guide walks through those label criteria in plain English, explains why the BMI numbers are what they are, shows how the diabetes versions of these drugs differ, and ends with questions to take to a clinician.

Educational only. This is not medical advice. Eligibility on paper is not the same as a decision that a medicine is right for you. Whether to start any GLP-1 medication is a decision to make with a licensed clinician who knows your full health history.

The short answer

For chronic weight management, the FDA-approved GLP-1-based medicines share almost the same core rule. According to their labels, they are approved, together with a reduced-calorie diet and increased physical activity, for:

• Adults with obesity, or
• Adults with overweight plus at least one weight-related health condition (the label term is “comorbid condition”).

In numbers, that has meant:

Group	BMI	Extra requirement
Obesity	30 or higher	None beyond being an adult
Overweight	27 to 29.9	At least one weight-related condition, such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea
Below 27	Under 27	Outside the label criteria for weight management

Those BMI cutoffs come from the enrollment rules of the pivotal trials and from FDA’s own approval announcements. When FDA approved Zepbound in November 2023, for example, it described the approved population as adults “with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol).” The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists the same two thresholds for weight-management medicines in general.

Not sure of your number? Our BMI calculator uses the CDC adult categories.

Which GLP-1 medicines this applies to

The label rule above applies to the medicines approved specifically for weight management. As of October 2026, the main GLP-1-based options are:

• Wegovy (semaglutide), as a weekly injection or a daily tablet
• Zepbound (tirzepatide), a weekly injection that acts on both GLP-1 and GIP receptors
• Foundayo (orforglipron), a daily small-molecule GLP-1 pill approved in 2026
• Saxenda (liraglutide) and its generics, an older daily injection

For a full rundown, including how each was approved, see which GLP-1 medications are FDA-approved for weight loss. If you are new to the class, start with what a GLP-1 medication is and how GLP-1s work for weight loss.

Rule 1: obesity (BMI 30 or higher)

If you are an adult with a BMI of 30 or more, you fall within the main weight-management indication of each of these labels. No additional diagnosis is required by the label itself.

The trials behind these approvals show where that number comes from. The Wegovy label describes several 68-week trials that enrolled adults “with obesity (BMI greater than or equal to 30 kg/m2) or with overweight (BMI 27 to 29.9 kg/m2) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension.” The main Zepbound weight trial used almost identical wording, and so did the oral Wegovy and Foundayo trials.

Average BMI in those trials was well above the minimum, often around 37 to 38. So the evidence is strongest for people with clearly established obesity, though everyone at 30 or above was eligible to enroll.

Rule 2: overweight (BMI 27 to 29.9) plus a weight-related condition

The second route covers adults with a BMI between 27 and 29.9 who also have at least one health problem linked to excess weight. This is where most of the confusion lives, so it is worth being precise.

Conditions the labels and trials name

The labels and FDA documents give examples rather than a complete list. Conditions named across them include:

• High blood pressure (hypertension), treated or untreated
• Dyslipidemia: high LDL cholesterol, high triglycerides or low HDL, treated or untreated
• Type 2 diabetes
• Obstructive sleep apnea
• Cardiovascular disease, such as a prior heart attack or stroke

Major medical centers describe the same picture. Yale Medicine’s February 2026 explainer lists type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, cardiovascular disease and MASH (a form of fatty liver inflammation) as examples.

What “at least one” means in practice

The label requires only one qualifying condition. But two practical points matter:

1. It has to be a real, documented diagnosis. A clinician will usually want to see a blood pressure reading, a lipid panel, a sleep study or a medical record, not just a self-report.
2. Insurers may be stricter than the label. Many plans set their own criteria for coverage. A plan might, for instance, require specific conditions or proof of previous weight-loss attempts. That is a coverage decision, not an FDA rule (more on this below).

Extra indications: heart disease, sleep apnea, liver disease and teens

Some products have additional approved uses that can matter for who is a candidate.

Wegovy and heart disease. Both the injection and the tablet are approved “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.” The trial behind this (called SELECT in the medical literature, Study 1 on the label) enrolled adults aged 45 and older with a BMI of 27 or higher and established cardiovascular disease, meaning a prior heart attack, prior stroke or peripheral arterial disease. People with diabetes were excluded from that trial.

Wegovy and fatty liver disease. The injection is also approved, under FDA’s accelerated approval pathway, for adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis.

Zepbound and sleep apnea. In December 2024 FDA approved Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity, which FDA called the first drug treatment option for certain patients with the condition. The two supporting trials enrolled adults without type 2 diabetes, some using positive airway pressure (PAP) therapy and some unable or unwilling to use it.

Adolescents. Wegovy injection is approved for patients aged 12 and older with obesity. The label says the pediatric trial enrolled adolescents “with a BMI corresponding to ≥95th percentile for age and sex.” The Wegovy tablet is approved for adults only, and the Zepbound label states that its “safety and effectiveness … have not been established in pediatric patients.” For children and teens, BMI is read on age- and sex-specific growth charts rather than with the adult cutoffs, so this is very much a decision for a pediatric clinician.

Why BMI 27 and 30, and what BMI misses

BMI is weight in kilograms divided by height in meters squared. The CDC classes adults with a BMI of 25 to under 30 as having overweight and 30 or more as having obesity, with obesity further split into class 1 (30 to under 35), class 2 (35 to under 40) and class 3 (40 or more).

Notice that the drug labels do not start at 25, where “overweight” begins. They start at 27, and only with a weight-related condition. Below 30, the medicines are positioned for people whose weight is already affecting their health, not simply for anyone above the healthy-weight range.

BMI is also a blunt tool, and the major guidelines say so plainly:

• The CDC calls BMI “a screening measure” that “should be considered with other factors when assessing an individual’s health.”
• The American Diabetes Association’s 2026 Standards of Care note that BMI “does not measure adipose tissue distribution or function” and is “especially prone to misclassification” in very muscular people, in people with low muscle mass and in some ethnic groups. It recommends confirming excess body fat with a measure such as waist circumference or waist-to-height ratio where feasible, while accepting that BMI remains usable in everyday practice.
• A 2025 Lancet Diabetes & Endocrinology Commission went further, recommending that BMI be used as “a surrogate measure of health risk at a population level” and for screening, “rather than as an individual measure of health,” and proposing a distinction between “preclinical” and “clinical” obesity based on whether excess fat is already impairing organ function or daily life.

None of this changes the FDA label criteria, which are still written around obesity and overweight as BMI-defined categories. But it explains why a clinician may look beyond the number, for example at waist size, blood tests and symptoms, when deciding whether treatment makes sense.

A note on Asian American patients

The weight-management labels do not set separate BMI thresholds by ethnicity. Some guidelines do, for other decisions: the ADA’s 2026 Standards, for example, suggest considering metabolic surgery in people with type 2 diabetes at a BMI of 30 or more, “or ≥27.5 kg/m2 in Asian American individuals.” One Wegovy trial was run specifically in East Asian adults in Japan and South Korea, with its own entry criteria. If you are of Asian heritage, ask your clinician how they interpret your BMI, because health risks can appear at lower values.

Who is usually not a candidate

The labels draw a clear line around a small number of situations and flag many others for caution. This is a high-level summary of what the labels say, not a checklist to clear yourself for treatment. Only a clinician who reviews your history can do that.

Label contraindications (do not use)

The Wegovy, Zepbound and Foundayo labels all list two contraindications:

• A personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2). This relates to the boxed warning: these drugs caused thyroid C-cell tumors in rodents, and it is unknown whether they do so in humans.
• A known serious allergic reaction (hypersensitivity) to the drug or any of its ingredients.

Pregnancy and breastfeeding

Weight loss is not appropriate during pregnancy. In the Zepbound label’s words, “weight loss offers no benefit to a pregnant patient and may cause fetal harm,” and both the Wegovy and Zepbound labels say to stop the medicine when pregnancy is recognized. The Wegovy label also advises stopping at least 2 months before a planned pregnancy because semaglutide stays in the body a long time, and says breastfeeding is not recommended while taking Wegovy tablets. NIDDK’s general advice for weight-management medicines is to avoid them during pregnancy or when planning one.

Situations the labels flag for caution

Beyond the hard contraindications, the labels describe conditions that do not automatically rule someone out but call for a careful conversation:

• Severe gastroparesis (very slow stomach emptying): both Wegovy and Zepbound labels say they are “not recommended” in this group.
• A history of pancreatitis. Acute pancreatitis has been seen with these drugs. FDA noted at Zepbound’s 2023 approval that it “has not been studied in patients with a history of pancreatitis.”
• Gallbladder disease, since gallstones were more common on treatment than on placebo.
• Diabetes treated with insulin or a sulfonylurea, because adding a GLP-1 can raise the risk of low blood sugar. The Wegovy label also notes that use in type 1 diabetes has not been evaluated.
• Diabetic retinopathy in people with type 2 diabetes, which the labels say needs monitoring.
• Kidney problems, because vomiting or diarrhea can lead to dehydration and kidney injury.
• Upcoming surgery or sedation, because of a reported risk of inhaling stomach contents under anesthesia; tell every clinician you are taking one.
• Oral birth control with tirzepatide: the Zepbound label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.
• Other GLP-1s: the labels say combining a GLP-1 product with another GLP-1 is not recommended.

For a deeper look at these risks, see our Side Effects hub and side-effects guide.

Wanting to lose weight for appearance alone

NIDDK states it bluntly: “never take a weight management medication only to improve the way you look.” These are medicines for a chronic disease with real side effects. If your weight is not affecting your health, the risk-benefit balance looks very different.

Diabetes GLP-1s vs weight-management GLP-1s

A common mix-up is treating the diabetes and weight-loss versions of these drugs as interchangeable. They share active ingredients but are separate products with separate approvals.

Active ingredient	Approved for type 2 diabetes	Approved for weight management
Semaglutide	Ozempic (injection), Rybelsus (tablet)	Wegovy (injection and tablet)
Tirzepatide	Mounjaro (injection)	Zepbound (injection)
Liraglutide	Victoza (injection)	Saxenda (injection)

According to its label, Ozempic is indicated for adults with type 2 diabetes, to improve blood sugar control, to reduce the risk of major cardiovascular events in those with established heart disease, and to reduce the risk of kidney disease getting worse in those with chronic kidney disease. Mounjaro is indicated to improve blood sugar control in adults and children 10 and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Neither label includes chronic weight management.

What this means in practice:

• You do not need diabetes to qualify for Wegovy, Zepbound or Foundayo. Several of their main weight trials actually excluded people with type 2 diabetes, while separate trials studied people who have it.
• If you do have type 2 diabetes, you might be prescribed either kind of product, depending on your goals, your other medicines and your coverage. The ADA’s 2026 Standards recommend that, for people with diabetes and overweight or obesity, the preferred obesity medicine be a GLP-1 or dual GIP/GLP-1 drug with greater weight-loss effect, naming semaglutide or tirzepatide.
• Using a diabetes product only for weight loss is off-label. Clinicians are legally allowed to prescribe off-label, and NIDDK notes you should “feel comfortable asking” whether a medicine is approved for your condition. But the dosing and evidence behind the weight-management products come from trials designed for that purpose.

For the molecules themselves, see what semaglutide is and what tirzepatide is, or our semaglutide vs tirzepatide guide.

Qualifying is not the same as being covered

Meeting the FDA label criteria answers one question: is this an approved use? Whether your insurer or Medicare will pay is a separate question with separate rules.

Medicare offers a clear example. Under the temporary Medicare GLP-1 Bridge, which started July 1, 2026, Medicare.gov says people with Part D drug coverage can get certain GLP-1s (Wegovy, Zepbound KwikPen and Foundayo) for a $50 monthly copayment if, when they start therapy, they are 18 or older and have:

• a BMI of 35 or higher, or
• a BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure or chronic kidney disease stage 3a or higher, or
• a BMI of 27 or higher plus prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms.

People who have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease are not eligible for the Bridge itself, because Medicare says their regular Part D plan may cover GLP-1s for those conditions. The clinician must also send a prescription, complete a prior authorization when requested and certify that the medicine is being used as part of a diet and exercise program.

Those rules are noticeably stricter than the FDA label at the lower end of the BMI range. Private insurers and employer plans set their own criteria too, and those vary widely. If cost is a factor, see our GLP-1 cost guide, semaglutide cost without insurance and the Costs Without Insurance hub.

The role of clinician judgment

The label is a floor, not a guarantee. A clinician who meets the criteria on paper still has to decide whether a GLP-1 is the right tool for you. The ADA’s Standards recommend that the first approach to obesity treatment, whether lifestyle and nutrition therapy, medication or surgery, be individualized “based on the person’s medical history, life circumstances, and preferences.”

In practice, a good prescriber will usually:

• Take a full history, including thyroid cancer in the family, pancreatitis, gallbladder disease, digestive problems, eating patterns, pregnancy plans and every medicine and supplement you take.
• Check measurements and labs, such as weight, height, waist, blood pressure and blood work for blood sugar, cholesterol and kidney function.
• Look at your other medicines. Some common drugs promote weight gain, and for people with diabetes and obesity the ADA recommends minimizing them whenever clinically appropriate.
• Set expectations and a follow-up plan. NIDDK notes that if someone does not lose at least 5% of their starting weight after 12 weeks on the full dose, a clinician will “probably advise you to stop taking it” or change the plan.
• Plan for the long term. Yale Medicine’s obesity specialists stress that the prescriber should ideally be “someone you can work with long term,” because obesity is a chronic disease and people who stop treatment often regain weight.

Clinicians who discuss this publicly tend to follow the same structure. A March 2026 Stony Brook Medicine episode on YouTube, for instance, sets aside separate segments for who is a good candidate, what conversations should happen before starting, and what makes someone not a strong candidate. That is the right order: eligibility first, then a frank conversation about fit.

The labels also approve these medicines “in combination with a reduced calorie diet and increased physical activity.” NIDDK puts it simply: medications “don’t replace physical activity or healthy eating habits.” Protein and strength training matter even more when appetite drops; see how much protein you need on a GLP-1 and strength training on GLP-1s.

In-person or telehealth: the criteria do not change

You can be assessed by a primary care clinician, an obesity medicine specialist, an endocrinologist or a licensed telehealth clinician. Yale Medicine notes that any licensed prescriber can prescribe these medicines, but that continuity and follow-up vary by provider.

Whichever route you choose, the label criteria are the same. A legitimate service will ask for your height, weight, health history and medicines, and should turn people away when treatment is not appropriate. Be wary of any seller that offers GLP-1s with no questions asked, or that markets “research” or unapproved products. Compounded semaglutide and tirzepatide are not FDA-approved products. Our guide to how telehealth weight-loss programs work covers FDA’s red flags and what a proper intake looks like. You can also explore the Telehealth hub.

Questions to bring to a clinician

Writing these down before an appointment can make the conversation far more useful:

1. Based on my BMI and health history, do I meet the label criteria for a weight-management GLP-1? Which condition, if any, counts in my case?
2. Is anything in my history a reason to avoid these medicines, such as family thyroid cancer, past pancreatitis, gallbladder problems or digestive issues?
3. Which product fits me best and why: injection or pill, weekly or daily, semaglutide, tirzepatide or another option?
4. How will my other medicines be affected? This includes diabetes medicines, birth control and anything with a narrow safety margin.
5. What results are realistic for someone like me, and how will we judge whether it is working?
6. What side effects should I expect early on, and which symptoms mean I should call you or seek urgent care?
7. How long would I likely stay on it, and what is the plan if I stop?
8. Will my insurance or Medicare cover it, and what documentation will a prior authorization need?
9. What nutrition, protein and exercise support will go with the prescription?
10. If I am planning a pregnancy, or might become pregnant, what should I do?

What people are asking online

On X, eligibility questions show up constantly. One recent post simply asked how to get a GLP-1 with a BMI under 27; others share the 30-and-27 rule in reply to promotions they see as careless, or discuss Medicare’s new Bridge pricing. That conversation shows real demand and real confusion. Social posts are not medical evidence, though, and some mix up label criteria, insurance rules and prices. When a post makes a claim about who qualifies, check it against the FDA label or Medicare.gov, both linked below.

The bottom line

FDA-approved GLP-1 weight-management medicines are for adults with obesity, or overweight plus at least one weight-related condition, which in practice means a BMI of 30 or more, or 27 or more with a condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea. A few have extra approved uses, including heart-risk reduction, sleep apnea, a form of fatty liver disease and treatment of teens with obesity.

A personal or family history of medullary thyroid cancer or MEN 2, a serious allergy to the drug, and pregnancy are clear stop signs. Many other conditions call for careful discussion rather than an automatic no. Diabetes products such as Ozempic and Mounjaro are not the same as their weight-management siblings, and meeting the label criteria does not guarantee coverage.

Above all, eligibility is the start of a conversation, not the end of one. Explore the rest of the GLP-1 Guide, our Semaglutide hub, Tirzepatide hub and Oral & New GLP-1s hub, or take our first 30 days guide to your next appointment.